GDC-6599 (Example 8) is an orally active TRPA1 inhibitor. GDC-6599 can be used to study TRPA1-mediated diseases such as pain.
References:
[1]. Jack Alexander Terrett, et al. Oxadiazole transient receptor potential channel inhibitors. Patent US20190284179A1.
















